|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/12/13 Biolase, Inc 10-Q 9/30/13 65:8.2M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 543K
2: EX-4 Ex-4.2 HTML 65K
3: EX-4 Ex-4.3 HTML 63K
4: EX-10 Ex-10.4 HTML 47K
5: EX-31 Ex-31.1 HTML 27K
6: EX-31 Ex-31.2 HTML 28K
7: EX-32 Ex-32.1 HTML 21K
8: EX-32 Ex-32.2 HTML 22K
64: R1 Document and Entity Information HTML 41K
45: R2 Consolidated Balance Sheets HTML 136K
42: R3 Consolidated Balance Sheets (Parenthetical) HTML 48K
17: R4 Consolidated Statements Of Operations And HTML 105K
Comprehensive Loss
44: R5 Consolidated Statements Of Cash Flows HTML 144K
31: R6 Basis of Presentation HTML 55K
57: R7 Recent Accounting Pronouncements HTML 30K
32: R8 Stock-Based Awards and Per Share Information HTML 222K
34: R9 Inventory HTML 37K
18: R10 Property, Plant, and Equipment HTML 53K
33: R11 Intangible Assets and Goodwill HTML 101K
56: R12 Accrued Liabilities and Deferred Revenue HTML 110K
52: R13 Lines Of Credit and Other Borrowings HTML 55K
43: R14 Commitments and Contingencies HTML 42K
61: R15 Segment Information HTML 56K
55: R16 Concentrations HTML 28K
15: R17 Income Taxes HTML 41K
20: R18 Subsequent Event HTML 22K
60: R19 Accounting Policies (Policies) HTML 114K
63: R20 Stock-Based Awards and Per Share Information HTML 192K
(Tables)
65: R21 Inventory (Tables) HTML 34K
62: R22 Property, Plant, and Equipment (Tables) HTML 49K
47: R23 Intangible Assets and Goodwill (Tables) HTML 93K
19: R24 Accrued Liabilities and Deferred Revenue (Tables) HTML 116K
30: R25 Segment Information (Tables) HTML 47K
23: R26 Basis of Presentation - Additional Information HTML 67K
(Detail)
22: R27 Classification of Compensation Expense Associated HTML 29K
with Share-Based Payments (Detail)
36: R28 Assumptions Used in Estimating Fair Value of Stock HTML 32K
Options Granted (Detail)
46: R29 Summary of Option Activity (Detail) HTML 72K
53: R30 Cash Proceeds Along with Fair Value Disclosures HTML 39K
Related to grants Exercises and Vesting Options
(Detail)
27: R31 Stock Based Awards and Per Share Information - HTML 115K
Additional Information (Detail)
37: R32 Components of Inventory (Detail) HTML 32K
59: R33 Inventory - Additional Information (Detail) HTML 25K
25: R34 Summary of Property, Plant, and Equipment (Detail) HTML 36K
50: R35 Property, Plant, and Equipment - Additional HTML 22K
Information (Detail)
51: R36 Intangible Assets Related to Accumulated HTML 52K
Amortization and Goodwill (Detail)
38: R37 Intangible Assets and Goodwill - Additional HTML 24K
Information (Detail)
21: R38 Components of Accrued Liabilities (Detail) HTML 43K
49: R39 Changes In Initial Product Warranty Accrual and HTML 38K
Expenses Under Initial and Extended Warranties
(Detail)
26: R40 Summary of Deferred Revenue (Detail) HTML 37K
35: R41 Lines of Credit and Other Borrowings - Additional HTML 111K
Information (Detail)
54: R42 Commitments and Contingencies - Additional HTML 32K
Information (Detail)
29: R43 Summary of Net Revenue by Geographic Location HTML 24K
(Detail)
48: R44 Segment Information - Additional Information HTML 30K
(Detail)
41: R45 Concentrations - Additional Information (Detail) HTML 31K
24: R46 Income Taxes - Additional Information (Detail) HTML 57K
58: R47 Subsequent Event - Additional Information (Detail) HTML 21K
40: XML IDEA XML File -- Filing Summary XML 91K
16: EXCEL IDEA Workbook of Financial Reports XLSX 134K
39: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.26M
9: EX-101.INS XBRL Instance -- biol-20130930 XML 1.59M
11: EX-101.CAL XBRL Calculations -- biol-20130930_cal XML 132K
12: EX-101.DEF XBRL Definitions -- biol-20130930_def XML 710K
13: EX-101.LAB XBRL Labels -- biol-20130930_lab XML 998K
14: EX-101.PRE XBRL Presentations -- biol-20130930_pre XML 800K
10: EX-101.SCH XBRL Schema -- biol-20130930 XSD 161K
28: ZIP XBRL Zipped Folder -- 0001564590-13-001200-xbrl Zip 135K
Exhibit 31.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Federico Pignatelli, certify that:
1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2013 of BIOLASE, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; |
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: November 12, 2013 |
By: |
|
|
|
|
|
|
|
|
Chief Executive Officer (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/12/13 | 8-K | ||
| For Period end: | 9/30/13 | |||
| List all Filings | ||||